This week, the first Digital therapeutics (DTx) for maternal mental health, MamaLift Plus™, was approved by the FDA. The treatment, developed by Curio, was studied by randomized control trial. Patients with mild to moderate postpartum depression who used the treatment improved by four or more points on the Edinburgh Postnatal Depression Scale (EPDS).